Диссертация (1141037), страница 29
Текст из файла (страница 29)
Semin. Arthritis Rheum., 1991, Vol. 20, p. 241-246.90. Ben-Chetrit E.; Ozdogan H. «Non-response to colchicine in FMF--definition, causes andsuggested solutions». Clin. Exp. Rheumatol., 2008, Vol. 26, р. 49-5191. Ben-Chetrit E.; Touitou I. «Familial mediterranean Fever in the world». Arthritis Rheum.,2009, 61, p. 1447-1453.92. Ben-Zvi I., Herskovizh C., Kukuy O.
et al. «Familial Mediterranean fever without MEFVmutations: a case–control study». Orphanet Journal of Rare Diseases, 2015, Vol. 10, p.34-3693. Beser O.F., Cokugras F. C., Kutlu T. «Association of familial Mediterranean fever inTurkish children with inflammatory bowel disease». Turk Pediatri Ars. 2014, Vol. 49(3),p.198-202.17694. Cantarini L.; Vitale A.; Lucherini O.M.
et al. «The labyrinth of autoinflammatorydisorders: a snapshot on the activity of a third-level center in Italy». Clin. Rheumatol.,2015, 34, 17-28.95. Celikbilek M., Dogan S., Akyol L. et al. «Neutrophil–Lymphocyte Ratio in Patients WithFamilial Mediterranean Fever». Journal of Clinical Laboratory Analysis 2015, vol.
29, p.80–83.96. Cetin P., Sari I., Sozeri B. et al. «Efficacy of interleukin-1 targeting treatments in patientswith familial mediterranean fever». Inflammation, 2015, vol. 38, p. 27-31.97. Centola M., Chen X., Sood R. et al. «Construction of an ∼700-kb Transcript Map Around theFamilial Mediterranean Fever Locus on Human Chromosome 16p13.3». Genome Res, 1998,no. 8, p.1172-119198. Ceylan O., Ozgur S., Orun U.
et al. «Assessment of left ventricular functions with tissueDoppler, strain, and strain rate echocardiography in patients with familial Mediterraneanfever». Anatol J Cardiol 2015, vol.15, p. 663-66899. Comak E., Tufekci O., Kılıcbay F. et al. «Febrile seizures in children with familialMediterranean fever: Coincidence or association?» European journal ofpaediatricneurology 2015, vol.19, р. 572 -576100. Coskun S., Kurtgoz S., Keskin E.
et al. «Frequency of mutations in Mediterranean fevergene, with gender and genotype–phenotype correlations in a Turkish population». J.Genet. 2015, vol. 94 , p. 629–635101. Cronstein B.N.; Molad Y.; Reibman J. et al. «Colchicine alters the quantitative andqualitative display of selectins on endothelial cells and neutrophils». J. Clin. Invest., 1995,Vol. 96, p. 994-1002.102.Chae, J.J., Aksentijevich, I., Kastner, D.L. «Advances in the understanding offamilial Mediterranean fever and possibilities for targeted therapy». Br.
J. Haematol.,2009, Vol. 146, p. 467- 478.103. Chae, J.J., Wood, G., Masters, S.L. et al. «The B30.2 domain of pyrin, the familialMediterranean fever protein, interacts directly with caspase-1 to modulate IL-1betaproduction». Proc. Natl. Acad. Sci. U.S.A. 2006104.
Debeljak M., Toplak N., Abazi N., Szabados B. «The carrier rate and spectrum ofMEFV gene mutations in central and southeastern European populations».Rheumatol 2015, vol. 33 (Suppl. 94): p. 19-23.Clin Exp177105. Demirkaya E., Erer B., Ozen S., Ben‑Chetrit E. «Efficacy and safety of treatments inFamilial Mediterranean fever: a systematic review» J. Rheumatol Int.
2015, online version,doi:10.1007/s00296-015-3408-9106. Demirkaya E., Saglam C., Turker T. et al. «Performance of Different DiagnosticCriteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from aMulticenter International Registry».The Journal of Rheumatology, 2016, Vol. 43, no. 1.,p. 154-160107. Dinarello C.A.; Wolff S.M.; Goldfinger S.E. et al.
«Colchicine therapy for familialMediterranean fever. A double-blind trial». N. Engl. J. Med., 1974, vol. 291, p. 934-937.108.Dogan H., Bayrak O., Emet M. et el. «Familial Mediterranean fever gene mutations innorth-eastern part of Anatolia with special respect to rare mutations». J. Gene 2015,no.568, p.170–175109.Erer B., Demirkaya E., Ozen S., Kallinich T. «What is the best acute phase reactantfor familial Mediterranean fever follow-up and its role in the prediction of complications?A systematic review». J.
Rheumatol Int., 2015 online version, doi:10.1007/s00296-0153413-z.110.Eroglu, F.K.; Besbas, N.; Topaloglu, R.; Ozen, S. «Treatment of colchicine-resistantFamilial Mediterranean fever in children and adolescents». Rheumatol. Int., 2015, no. 35,p. 1733-1737.111.Fujikura K. «Global epidemiology of Familial Mediterranean fever mutations usingpopulation exome sequences». Molecular Genetics & Genomic Medicine, 2015; vol. 3(4),p. 272–282112.Gershoni-Baruch R., R.
Brik, M. Shinawi, A. Livneh «The differential contribution ofMEFV mutant alleles to the clinical profile of familial Mediterranena fever» Eur. J. Hum.Genet., 2002, no.10., p. 145-149.113.Gershoni-Baruch R, Brik R, Zacks N, et al. «The contribution of genotypes at theMEFV and SAA1 loci to amyloidosis and disease severity in patients with familialMediterranean fever».
Arthritis Rheum , 2003, vol. 48, p.1149–1155.114.Giancane G., Ter-Haar N. M., Wulffraat N. et al. «Evidence-based recommendationsfor genetic diagnosis of familial Mediterranean fever». Ann Rheum Dis , 2015, no. 74, p.635–641.178115.Goldfinger S.E. «Colchicine for familial Mediterranean fever». N. Engl. J. Med., 1972,no 287, p. 1302.116.Goldstein R.C.; Schwabe A.D.
«Prophylactic colchicines therapy in familialMediterranean fever. A controlled, double-blind study». Ann. Intern. Med., 1974, no. 81, p.792-794.117.Gul A., Ozdogan H., Erer B. et al. «Efficacy and safety of canakinumab in adolescentsand adults with colchicineresistant familial Mediterranean fever». Arthritis Research &Therapy. 2015,no.17, p. 243-247118.Hashkes P.
J., Huang B. «The Familial Mediterranean Fever (FMF) 50 Score: Does itWork in a Controlled Clinical Trial? Re-Analysis of the Trial of Rilonacept for Patientswith Colchicine- resistant or Intolerant FMF». IMAJ, 2015; vol. 17, p. 137–140119.Ibrahim J.-N., Chouery E., Lecron J.-C. et al. «Study of the association of IL-1b andIL-1RA gene polymorphisms with occurrence and severity of Familial Mediterraneanfever». European Journal of Medical Genetics 2015, vol.
58, p. 668-673120.Kallinich T., Haffner D., Niehue T. et al. «Colchicine use in children and adolescentswith familial Mediterranean fever: literature review and consensus statement». Pediatrics,2007, no. 119, p. 474-483.121.Kastner D. L. «FMF: the genetics of inflammation».
Hosp. Pract., 1998, no. 15, p.131-158.122.Kastner D.L. «Intermittent and periodic arthritic syndromes». In Arthritis and alliedconditions, 13th ed. (ed. W.J. Koopman). Williams and Wilkins, Baltimore, MD. 1996. p.1279-1306123.Kuijk L.M., Hoffman H.L., Neven B., Frenkel J. «Episodic AutoinflammatoryDisorders in Children.
In: Handbook of Systemic Autoimmune Disease». Pediatrcs inSystemic Autoimmune Disease. R. Cimas, T. Lehman (eds). Elselvier, 2008; V.6, pp.119–35.124.Langevitz P, Zemer D, Livneh A. «Protracted febrile myalgia in patients with familialMediterranean fever». J. Rheumatol ,1994;no 21, pp.1708-1709.125.Lieber M., Kallinich T., Lohse P. et al.«Increased serum concentrations ofneutrophil-derived protein S100A12 in heterozygous carriers of MEFV mutations». ClinExp Rheumatol, 2015;no. 33 (Suppl. 94): pp.113-116.179126.Livneh A., Langevitz P., Zemer D. et al. «Criteria for the diagnosis of familialMediterranean fever».
Arthr Rheum, 1997; no. 40, pp.1879–85.127.Livneh A.; Zemer D.; Langevitz P. et al. «Colchicine treatment of AA amyloidosis offamilial Mediterranean fever. An analysis of factors affecting outcome». Arthritis Rheum.,1994, no. 37, pp. 1804-1811.128.Livneh A.; Zemer D.; Siegal B. et al.
«Colchicine prevents kidney transplantamyloidosis in familial Mediterranean fever». Nephron, 1992, no. 60, pp. 418-422.129.Marzouk H., Lotfy H. M., Farag Y. et al. «Mean Platelet Volume and Splenomegaly asUseful Markers of Subclinical Activity in Egyptian Children with Familial MediterraneanFever: A Cross-Sectional Study». International Journal of Chronic Diseases, 2015, ArticleID 152616.130.Migita K., Izumi Y., Fujikawa K.
et al. «Dysregulated mature IL-1b production infamilial Mediterranean fever» . Rheumatology, 2015, no. 54, pp. 660-665.131.Milhavet F., Cuisset L., Hoffman H.M. et al. «The infevers autoinflammatory mutationonline registry: update with new genes and functions».
Hum. Mutat., 2008, no. 29, pp.803-808.132.Mukhin N. A., Kozlovskaya L. V. , Bogdanova M. V., Rameev V. V. «Predictors ofAA amyloidosis in familial Mediterranean fever» . Rheumatol Int 2015, no. 35, pp.1257–1261.133.Neocleous V., Costi C., Kyriakou C. «Familial Mediterranean Fever Associated withMEFV Mutations in a Large Cohort of Cypriot Patients». Annals of Human Genetics,2014, no. 00,pp.1–8134.Nogueira A.C., Neubert R., Helge H., Neubert D.
«Thalidomide and the immunesystem. Simultaneous up- and down-regulation of different integrin receptors on humanwhite blood cells». Life Sci., 1994, no. 55, pp. 77-92.135.Onen F. «Familial Mediterranean fever». Rheumatol. Int.,2006, no. 26, pp. 489-496.136.Ozen S., Batu E. D. «The myths we believed in familial Mediterranean fever: whathave we learned in the past years?» Semin Immunopathol, 2015, no. 37, рp.
363–369137.Ozen S.; Demirkaya E.; Amaryan G. et al. «Results from a multicentre internationalregistry of familial Mediterranean fever: impact of environment on the expression of amonogenic disease in children». Ann. Rheum. Dis., 2014, no.
73, pp. 662-667.180138.Ozen S., Demirkaya E., Erer B. et al. «EULAR recommendations for the managementof familial Mediterranean fever». Ann Rheum Dis, 2016;no. 0, pp. 1–8.139.Ozen S., Frenkel J., Ruperto N. et al. «The Eurofever Project: towards better care forautoinflammatory diseases». Eur. J. Pediatr., 2011, no. 170, pp. 445-452.140.Ozer S., YılmazR., Sonmezgoz E. et al. «Simple Markers for SubclinicalInflammation in Patients with Familial Mediterranean Fever». Med Sci Monit, 2015, no.21, pp.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
